Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) announced its earnings results on Friday. The specialty pharmaceutical company reported ($0.83) earnings per share (EPS) for the quarter, Zacks reports.
Titan Pharmaceuticals Stock Up 1.3 %
NASDAQ:TTNP opened at $3.23 on Friday. Titan Pharmaceuticals has a 52-week low of $3.03 and a 52-week high of $14.80. The stock’s 50-day simple moving average is $3.72 and its 200 day simple moving average is $4.95.
Analyst Ratings Changes
Separately, StockNews.com assumed coverage on shares of Titan Pharmaceuticals in a report on Saturday. They set a “sell” rating for the company.
About Titan Pharmaceuticals
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.
Read More
- Five stocks we like better than Titan Pharmaceuticals
- Top Stocks Investing in 5G Technology
- Cold Front, Hot Stocks: Diesel Prices Propel Energy Leaders
- Upcoming IPO Stock Lockup Period, Explained
- Sustainable and Successful: 3 Climate ETFs Beating the Market
- What Investors Need to Know to Beat the Market
- Quantum Opportunity: Skywater Technology’s Long-Term Potential
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
